Myasthenia gravis (MG) is an autoimmune disease characterized by ptosis, fatigue, and muscle weakness, caused by the association of pathogenic autoantibodies with postsynaptic membrane proteins at neuromuscular junctions. Eighty percent to 90% of cases are mediated by antibodies directed against the acetylcholine receptor (AChR).
GemPharmatech has independently developed two disease models: the AchRα97-116 induced experimental autoimmune myasthenia gravis (EAMG) and the MG patient derived PBLs NCG mouse model.
1. AchRα97-116 induced EAMG model
Serum total IgG/anti-AChR IgG/TGFβ
Gastrocnemius muscle HE staining
2. MG patient derived PBLs NCG model
Immune cell subpopulations
Blood
Spleen
Plasma assay
Pathological analysis (W7)
For further information, please feel free to contact us directly at: